John Wiley & Sons : Radavirsen Performs Well in Early Influenza Trial
September 20, 2017 at 12:15 am EDT
Share
A phase 1 clinical trial published in the British Journal of Clinical Pharmacology found that radavirsen-an antisense oligomer that inhibits the production of certain influenza proteins-is safe and well-tolerated in healthy individuals. Additional studies on radavirsen's potential as a treatment for influenza are warranted
In the 56-participant trial, pharmacokinetic analyses indicated that at 8mg/kg, radavirsen is expected to be effective in the treatment of influenza.
'This is the first demonstration of the safety and tolerability and pharmacokinetics of an antisense oligonucleotide for the treatment of influenza A,' wrote the authors of the study.
Additional Information
Link to Study: http://doi.wiley.com/10.1111/bcp.13405
About Journal
The British Journal of Clinical Pharmacology (BJCP) contains papers and reports on all aspects of drug action in humans: invited review articles, original papers and correspondence. The journal enjoys a wide readership, bridging the gap between the medical profession, clinical research and the pharmaceutical industry.
John Wiley & Sons Inc. published this content on 20 September 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 20 September 2017 04:14:05 UTC.
Original documenthttp://newsroom.wiley.com/press-release/british-journal-clinical-pharmacology/radavirsen-performs-well-early-influenza-trial
Public permalinkhttp://www.publicnow.com/view/C3690E8B833E2AF1B0B8F90CAF3DE62F0BFDCC35
John Wiley & Sons, Inc. is a knowledge company. The Company is engaged in providing research, publishing, and knowledge solutions. The Company's segments include Research, Learning, and Held for Sale or Sold. Research segment is a provide peer-reviewed scientific, technical, and medical (STM) publishing, content platforms, and related services to academic, corporate, and government customers, academic societies, and individual researchers. The Learning segment provides scientific, professional, and education print and digital books, digital courseware to libraries, corporations, students, professionals, and researchers, as well as assessment services to businesses and professionals. The Company's Research Publishing products provide scientific, technical, medical, and scholarly journals, as well as related content and services, to academic, corporate, and government libraries, learned societies, and individual researchers, and other professionals.
JOHN WILEY & SONS, INC. 
